MA39253B1 - Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr - Google Patents
Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxrInfo
- Publication number
- MA39253B1 MA39253B1 MA39253A MA39253A MA39253B1 MA 39253 B1 MA39253 B1 MA 39253B1 MA 39253 A MA39253 A MA 39253A MA 39253 A MA39253 A MA 39253A MA 39253 B1 MA39253 B1 MA 39253B1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted bicyclic
- compounds used
- rxr agonists
- bicyclic heteroaryl
- heteroaryl compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La présente invention se rapporte à certains composés bicycliques substitués de formule (i), qui sont des agonistes de rxr et sont par conséquent utiles dans le traitement de certains troubles pouvant être empêchés ou traités par l'activation de ce récepteur. L'invention concerne également des composés, leurs méthodes de préparation, des compositions pharmaceutiques contenant ces composés et des utilisations de ces composés dans le traitement de certains troubles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN161CH2014 | 2014-01-14 | ||
PCT/IN2015/000010 WO2015107549A1 (fr) | 2014-01-14 | 2015-01-09 | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39253A1 MA39253A1 (fr) | 2018-06-29 |
MA39253B1 true MA39253B1 (fr) | 2018-09-28 |
Family
ID=52815068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39253A MA39253B1 (fr) | 2014-01-14 | 2015-01-09 | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr |
Country Status (21)
Country | Link |
---|---|
US (1) | US9862713B2 (fr) |
EP (1) | EP3094626B1 (fr) |
JP (1) | JP6625057B2 (fr) |
KR (1) | KR102372599B1 (fr) |
CN (1) | CN107074800B (fr) |
AU (1) | AU2015207690B2 (fr) |
BR (1) | BR112016016348B1 (fr) |
CA (1) | CA2936162C (fr) |
CL (1) | CL2016001803A1 (fr) |
DK (1) | DK3094626T3 (fr) |
ES (1) | ES2795660T3 (fr) |
MA (1) | MA39253B1 (fr) |
MX (1) | MX2016009219A (fr) |
MY (1) | MY192609A (fr) |
PH (1) | PH12016501393A1 (fr) |
PL (1) | PL3094626T3 (fr) |
PT (1) | PT3094626T (fr) |
RU (1) | RU2721283C2 (fr) |
SG (1) | SG11201605721XA (fr) |
WO (1) | WO2015107549A1 (fr) |
ZA (1) | ZA201605102B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106565761A (zh) * | 2016-11-15 | 2017-04-19 | 贵州大学 | 一种4‑羧基苯硼酸的制备工艺 |
CN112047901B (zh) * | 2020-09-21 | 2023-01-24 | 自然资源部第三海洋研究所 | 苯并噻唑杂萜类化合物及其衍生物以及制备方法与应用 |
US11919873B1 (en) | 2023-08-29 | 2024-03-05 | King Faisal University | 1,3-benzothiazol-2-yl-N′-(benzoyloxy)ethanimidamide as an antitumor and antimicrobial compound |
US11851413B1 (en) | 2023-08-29 | 2023-12-26 | King Faisal University | 1,3-benzothiazol-2-yl-N'-[(naphthalene-1-carbonyl)oxy]ethanimidamide as an antitumor and antimicrobial compound |
US11912676B1 (en) | 2023-08-29 | 2024-02-27 | King Faisal University | N'-[(4-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide as an antitumor and antimicrobial compound |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK158947C (da) | 1982-07-06 | 1991-01-21 | Hoffmann La Roche | Tetrahydronaphthalin-,benzofuran- og benzothiophenderivater, fremstilling og anvendelse deraf samt rodenticid indeholdende saadanne derivater |
GR78888B (fr) * | 1982-07-06 | 1984-10-02 | Hoffmann La Roche | |
US5420145A (en) * | 1993-03-22 | 1995-05-30 | Koichi Shudo | Carboxylic acid derivative |
EP0671005A1 (fr) * | 1992-11-25 | 1995-09-13 | La Jolla Cancer Research Foundation | Formation d'un homodimere contenant des recepteurs de retinoide x (rxr), composes aromatiques bicycliques pontes et leur utilisation dans la modulation de l'expression genique |
WO1997010813A1 (fr) * | 1995-09-18 | 1997-03-27 | Ligand Pharmaceuticals Incorporated | Antagonistes de ppar gamma pour le traitement de l'obesite |
PT873295E (pt) * | 1995-10-06 | 2003-08-29 | Ligand Pharm Inc | Moduladores de rxr selectivos para dimeros para a sua utilizacao |
JPH10338658A (ja) * | 1997-04-08 | 1998-12-22 | Hoechst Marion Roussel Kk | レチノイド作用調節剤 |
US6624154B1 (en) * | 1999-04-23 | 2003-09-23 | Bristol-Myers Squibb Company | Compositions and methods for treatment of hyperproliferative diseases |
ATE365158T1 (de) * | 1999-04-28 | 2007-07-15 | Inst Med Molecular Design Inc | Pyrimidincarbonsäurederivate |
DE102004026532A1 (de) * | 2004-05-29 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Oxazol-Benzoisothiazoldioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
AU2006291234A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
JP2009513570A (ja) * | 2005-09-30 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしての複素環式アミド誘導体 |
JP2009512637A (ja) * | 2005-09-30 | 2009-03-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしてのジヒドロ−[1h]−キノリン−2−オン誘導体 |
EP1937640A2 (fr) * | 2005-09-30 | 2008-07-02 | Janssen Pharmaceutica N.V. | Derives de 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one utilises en tant qu'agonistes du recepteur rxr pour le traitement de la dyslipidemie, de l'hypercholesterolemie et du diabete |
PE20080714A1 (es) * | 2006-06-05 | 2008-07-31 | Novartis Ag | DERIVADOS HETEROCICLICOS COMO MODULADORES DE LA ACTIVIDAD DE LA ESTEARIL-CoA-DESATURASA |
AU2007292816B2 (en) * | 2006-09-07 | 2011-11-17 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
JP5255994B2 (ja) * | 2008-11-04 | 2013-08-07 | 国立大学法人 岡山大学 | 核内受容体リガンド |
JP2010280585A (ja) * | 2009-06-02 | 2010-12-16 | Okayama Univ | Rxr作動性物質を有効成分とする鎮痛剤 |
WO2012112623A2 (fr) * | 2011-02-14 | 2012-08-23 | Sloan-Kettering Institute For Cancer Research | Modulateurs des rxrg destinés à traiter le cancer |
-
2015
- 2015-01-09 CN CN201580014389.8A patent/CN107074800B/zh active Active
- 2015-01-09 KR KR1020167022235A patent/KR102372599B1/ko active IP Right Grant
- 2015-01-09 PT PT157149642T patent/PT3094626T/pt unknown
- 2015-01-09 PL PL15714964T patent/PL3094626T3/pl unknown
- 2015-01-09 SG SG11201605721XA patent/SG11201605721XA/en unknown
- 2015-01-09 AU AU2015207690A patent/AU2015207690B2/en active Active
- 2015-01-09 MY MYPI2016001300A patent/MY192609A/en unknown
- 2015-01-09 US US15/111,585 patent/US9862713B2/en active Active
- 2015-01-09 DK DK15714964.2T patent/DK3094626T3/da active
- 2015-01-09 WO PCT/IN2015/000010 patent/WO2015107549A1/fr active Application Filing
- 2015-01-09 EP EP15714964.2A patent/EP3094626B1/fr active Active
- 2015-01-09 BR BR112016016348-6A patent/BR112016016348B1/pt active IP Right Grant
- 2015-01-09 JP JP2016547014A patent/JP6625057B2/ja active Active
- 2015-01-09 ES ES15714964T patent/ES2795660T3/es active Active
- 2015-01-09 RU RU2016128529A patent/RU2721283C2/ru active
- 2015-01-09 MX MX2016009219A patent/MX2016009219A/es unknown
- 2015-01-09 MA MA39253A patent/MA39253B1/fr unknown
- 2015-01-09 CA CA2936162A patent/CA2936162C/fr active Active
-
2016
- 2016-07-14 PH PH12016501393A patent/PH12016501393A1/en unknown
- 2016-07-14 CL CL2016001803A patent/CL2016001803A1/es unknown
- 2016-07-21 ZA ZA2016/05102A patent/ZA201605102B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CL2016001803A1 (es) | 2017-03-17 |
JP6625057B2 (ja) | 2019-12-25 |
PH12016501393B1 (en) | 2017-02-06 |
CN107074800A (zh) | 2017-08-18 |
CA2936162C (fr) | 2023-10-17 |
ES2795660T3 (es) | 2020-11-24 |
US9862713B2 (en) | 2018-01-09 |
MA39253A1 (fr) | 2018-06-29 |
CN107074800B (zh) | 2019-11-12 |
SG11201605721XA (en) | 2016-08-30 |
PL3094626T3 (pl) | 2020-07-13 |
EP3094626A1 (fr) | 2016-11-23 |
AU2015207690B2 (en) | 2018-09-27 |
KR102372599B1 (ko) | 2022-03-10 |
DK3094626T3 (da) | 2020-05-25 |
PH12016501393A1 (en) | 2017-02-06 |
MY192609A (en) | 2022-08-29 |
PT3094626T (pt) | 2020-05-22 |
US20160333004A1 (en) | 2016-11-17 |
EP3094626B1 (fr) | 2020-02-19 |
KR20160125958A (ko) | 2016-11-01 |
ZA201605102B (en) | 2017-07-26 |
MX2016009219A (es) | 2017-03-06 |
AU2015207690A1 (en) | 2016-09-01 |
RU2721283C2 (ru) | 2020-05-18 |
RU2016128529A (ru) | 2018-02-20 |
CA2936162A1 (fr) | 2015-07-23 |
BR112016016348A2 (fr) | 2017-08-08 |
RU2016128529A3 (fr) | 2018-08-28 |
JP2017502999A (ja) | 2017-01-26 |
WO2015107549A1 (fr) | 2015-07-23 |
BR112016016348B1 (pt) | 2022-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41562B1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
MA38483A1 (fr) | Inhibiteurs de l'ido | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA40955A (fr) | 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 | |
MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA40290A1 (fr) | Agents immunorégulateurs | |
MA39783A (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
MA47043B1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
EA201790806A1 (ru) | Иммунорегулирующие средства | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA41179A (fr) | Composés inhibiteurs de parg | |
MA39193B1 (fr) | Modulateurs du gpr6 à base de tétrahydropyridopyrazines | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
MA46490A1 (fr) | Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués | |
MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists |